The current stock price of MMSI is 86.59 USD. In the past month the price increased by 4.28%. In the past year, price decreased by -16.66%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 19.39 | 15.49B | ||
| SOLV | SOLVENTUM CORP | 14.35 | 14.79B | ||
| ALGN | ALIGN TECHNOLOGY INC | 15.22 | 10.56B | ||
| LNTH | LANTHEUS HOLDINGS INC | 9.88 | 3.90B | ||
| HAE | HAEMONETICS CORP/MASS | 16.95 | 3.81B | ||
| ICUI | ICU MEDICAL INC | 18.65 | 3.66B | ||
| XRAY | DENTSPLY SIRONA INC | 7.18 | 2.26B | ||
| UFPT | UFP TECHNOLOGIES INC | 26.27 | 1.75B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.32B | ||
| NEOG | NEOGEN CORP | 19.93 | 1.30B | ||
| EMBC | EMBECTA CORP | 4.29 | 746.04M | ||
| BVS | BIOVENTUS INC - A | 12.86 | 628.15M |
Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. The company is headquartered in South Jordan, Utah and currently employs 7,400 full-time employees. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. The company also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.
MERIT MEDICAL SYSTEMS INC
1600 West Merit Park Way
South Jordan UTAH 84095 US
CEO: Fred P. Lampropoulos
Employees: 7400
Phone: 18012531600
Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. The company is headquartered in South Jordan, Utah and currently employs 7,400 full-time employees. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. The company also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.
The current stock price of MMSI is 86.59 USD. The price decreased by -0.94% in the last trading session.
MMSI does not pay a dividend.
MMSI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
The PE ratio for MERIT MEDICAL SYSTEMS INC (MMSI) is 23.28. This is based on the reported non-GAAP earnings per share of 3.72 and the current share price of 86.59 USD.
The Revenue of MERIT MEDICAL SYSTEMS INC (MMSI) is expected to grow by 11.45% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
MERIT MEDICAL SYSTEMS INC (MMSI) has a market capitalization of 5.13B USD. This makes MMSI a Mid Cap stock.
ChartMill assigns a technical rating of 4 / 10 to MMSI. When comparing the yearly performance of all stocks, MMSI is a bad performer in the overall market: 76% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to MMSI. MMSI scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
Over the last trailing twelve months MMSI reported a non-GAAP Earnings per Share(EPS) of 3.72. The EPS increased by 10.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.02% | ||
| ROA | 4.5% | ||
| ROE | 7.74% | ||
| Debt/Equity | 0.48 |
17 analysts have analysed MMSI and the average price target is 105.06 USD. This implies a price increase of 21.33% is expected in the next year compared to the current price of 86.59.
For the next year, analysts expect an EPS growth of 8.72% and a revenue growth 11.45% for MMSI